CEL-SCI CORPORATION Increase (Decrease) in Deferred Rent Receivables (Deprecated 2012-01-31)
CEL-SCI CORPORATION (CVM) reported Increase (Decrease) in Deferred Rent Receivables (Deprecated 2012-01-31) of $629.68 thousand for the 12-month period ending 2011-09-30, per its 10-K filed 2011-12-23.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRentReceivables · last filed 2011-12-23
- CEL-SCI CORPORATION increase (decrease) in deferred rent receivables (deprecated 2012-01-31) for the quarter ending 2011-09-30 was $161.65K, a 19.80% decline year-over-year.
- CEL-SCI CORPORATION increase (decrease) in deferred rent receivables (deprecated 2012-01-31) for the quarter ending 2010-09-30 was $201.57K.
- CEL-SCI CORPORATION increase (decrease) in deferred rent receivables (deprecated 2012-01-31) for fiscal 2011 was $629.68K, a 34.12% decline from fiscal 2010.
- CEL-SCI CORPORATION increase (decrease) in deferred rent receivables (deprecated 2012-01-31) for fiscal 2010 was $955.84K, a 53.59% increase from fiscal 2009.
- CEL-SCI CORPORATION increase (decrease) in deferred rent receivables (deprecated 2012-01-31) for fiscal 2009 was $622.35K.
| Period end | Increase (Decrease) in Deferred Rent Receivables (Deprecated 2012-01-31) 3 month | Increase (Decrease) in Deferred Rent Receivables (Deprecated 2012-01-31) 9 month | Increase (Decrease) in Deferred Rent Receivables (Deprecated 2012-01-31) 12 month |
|---|---|---|---|
| 2011-09-30 | $161.65K derived: 10-K 12 month − 10-Q 9 month · filed 2011-12-23 | $629.68K 10-K · filed 2011-12-23 | |
| 2011-06-30 | $468.03K 10-Q · filed 2011-08-09 | ||
| 2010-09-30 | $201.57K derived: 10-K 12 month − 10-Q 9 month · filed 2011-12-23 | $955.84K 10-K · filed 2011-12-23 | |
| 2010-06-30 | $754.28K 10-Q · filed 2011-08-09 | ||
| 2009-09-30 | $622.35K 10-K · filed 2011-12-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |